NPRA (Malaysia)

The National Pharmaceutical Regulatory Agency (NPRA — Bahagian Regulatori Farmasi Negara) is Malaysia's national regulator for human medicines, biologicals, vaccines, cosmetics, traditional and complementary medicines and health supplements. NPRA serves as the secretariat of the Drug Control Authority (DCA — Pihak Berkuasa Kawalan Dadah), the statutory body established under the Sale of Drugs Act 1952 and Control of Drugs and Cosmetics Regulations 1984 that makes registration decisions. NPRA operates from Petaling Jaya, Selangor, and reports to the Ministry of Health (MOH). Medical devices are regulated separately by the Medical Device Authority (MDA) under the Medical Device Act 2012.

Malaysia is a PIC/S member since 2002 — one of the earliest Asian participants — and its GMP inspectorate is well established internationally. NPRA reached WHO Maturity Level 3 for medicines regulation in 2021. Reliance pathways honour approvals from FDA, EMA, MHRA, Health Canada, TGA, Swissmedic and PMDA. Generics and biosimilars follow the ASEAN Common Technical Dossier (ACTD) format; innovator products may be submitted in ICH CTD format. Traditional medicines and health supplements follow separate DCA guidelines with distinct efficacy and safety requirements.

GMP inspections of overseas manufacturers are risk-based; PIC/S GMP certificates support desk review, while biologicals, sterile products and vaccines attract on-site inspection. NPRA also enforces the National Pharmaceutical Serialisation and Traceability programme. V5 Ultimate maps directly onto NPRA expectations — bound e-signatures, ALCOA+ batch records, deviation/CAPA workflow, and a per-country dossier pack — with the paired guide at /glossary/malaysia-npra.